Hepatitis: After HCV cure, HBV cure?

Nature Reviews Gastroenterology and Hepatology

Volumn 12, Issue 7, 2015, Pages 376-377

  Lucifora, Julie ^a   Trepo, Christian ^a  

^a CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; BIRINAPANT; ENTECAVIR; GAMMA INTERFERON; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN 1; INHIBITOR OF APOPTOSIS PROTEIN ANTAGONIST; TENOFOVIR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG; INHIBITOR OF APOPTOSIS PROTEIN;

ANTIBODY TITER; ANTIVIRAL THERAPY; CD4+ T LYMPHOCYTE; DRUG RESEARCH; DRUG TARGETING; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOLOGICAL TOLERANCE; MOUSE MODEL; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; TUNEL ASSAY; VIRAL CLEARANCE; VIRUS CELL INTERACTION; VIRUS INHIBITION; VIRUS REPLICATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DRUG EFFECTS; LIVER; LIVER CELL; METABOLISM; MOUSE; PATHOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; HEPATITIS B; HEPATITIS B VIRUS; HEPATOCYTES; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LIVER; MICE; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84934846678     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2015.103     Document Type: Short Survey

References (10)

1. Pawlotsky, J. M. et al. From non-A, non-B hepatitis to hepatitis C virus cure. J. Hepatol. 62 (Suppl.), S87-S99 (2015).
2. Zoulim, F., Locarnini, S. Management of treatment failure in chronic hepatitis B. J. Hepatol. 56 (Suppl. 1), S112-S122 (2012).
3. Ebert, G. et al. Cellular inhibitor of apoptosis proteins prevent clearance of hepatitis B virus. Proc. Natl Acad. Sci. USA 112, 5797-5802 (2015).
4. Wang, K., Lin, B. Inhibitor of apoptosis proteins (IAPs) as regulatory factors of hepatic apoptosis. Cell Signal. 25, 1970-1080 (2013).
5. Thimme, R. et al. CD8+ T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J. Virol. 77, 68-76 (2003).
6. Ebert, G. et al. Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis. Proc. Natl Acad. Sci. USA 112, 5803-5808 (2015).
7. Lan, P. et al. Therapeutic recovery of hepatitis B virus (HBV)-induced hepatocyte-intrinsic immune defect reverses systemic adaptive immune tolerance. Hepatology 58, 73-85 (2013).
8. Wisskirchen, K. et al. New pharmacological strategies to fight enveloped viruses. Trends Pharmacol. Sci. 35, 470-478 (2014).
9. Lucifora, J. et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 343, 1221-1228 (2014).
10. Koh, S. et al. Engineered HBV-specific T cells: disentangling antiviral from killing capacity [abstract G04]. J. Hepatol. 62 (Suppl. 2), S188 (2015).